At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
Meloxicam 15 mg Tablets +1 moredrug
Likely dose
Meloxicam 15 mg Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Meloxicam 15 mg Tablets Versus Mobic® 15 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects
In Brief
A Phase 1 clinical trial evaluating Meloxicam 15 mg Tablets and Mobic® 15 mg Tablets for Healthy. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The objective of this study is to compare the rate and extent of absorption of meloxicam from a test formulation Meloxicam 15 mg Tablets versus the reference Mobic® 15 mg Tablets under fed conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
Primary CompletionFeb 2004
First PostedFeb 2009
TodayJul 2026
First PostedFeb 10, 2009
Enrollment StartFeb 1, 2004
Primary CompletionFeb 1, 2004
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Meloxicam 15 mg Tabletsdrug
1 x 15 mg, single-dose fed
Mobic® 15 mg Tabletsdrug
1 x 15 mg, single-dose fed